医学
淋巴瘤
淋巴增殖性病變
滤泡性淋巴瘤
B细胞
淋巴浆细胞淋巴瘤
边缘地带
美罗华
靶向治疗
疾病
华登氏巨球蛋白血症
肿瘤科
癌症研究
免疫学
内科学
癌症
抗体
作者
Elizabeth Smyth,Chan Y. Cheah,John F. Seymour
标识
DOI:10.1016/j.ctrv.2023.102510
摘要
The indolent B-cell non-Hodgkin lymphomas (B-NHL) comprise a heterogenous group of lymphoproliferative disorders characterized by slow growth kinetics and a relapsing/remitting course. Management has, until recently, been uniform across all indolent B-NHL subtypes. Improving insight into pathophysiological and molecular features of each disease has led to development of several targeted therapies. Consequently, each subtype must now be considered an individual entity. In this review, we consider the three commonest indolent B-NHLs: follicular lymphoma, marginal zone lymphoma and Waldenstrom's macroglobulinemia and review in detail the data on approved and emerging targeted therapeutic agents for each B-NHL subtype.
科研通智能强力驱动
Strongly Powered by AbleSci AI